Health care and combined oral contraceptive use at baseline
| Characteristic | Polycystic ovary syndrome* | Matched controls |
|---|---|---|
| Women, no. | 43 506 | 43 506 |
| Age, yr, mean | 28.7 | 28.9 |
| Health care use, % of women | ||
| Admission to hospital | 3.57 | 4.05 |
| Emergency department visit | 4.79 | 4.45 |
| Physician office visit | 51.31 | 50.08 |
| Combined oral contraceptive use | ||
| New user,† no. (%) of women | 20 150 (46.32) | 20 278 (46.61) |
| Prevalent user,‡ no. (%) of women | 23 356 (53.68) | 23 228 (53.39) |
| Prior time on combined oral contraceptives, mean, d | 103 | 103 |
| Total time on combined oral contraceptives, mean, d | 201 | 202 |
| Number of combined oral contraceptives products used in the past, mean | 0.6 | 0.6 |
| Combined oral contraceptive, % of women | ||
| Desogestrel, μg ethinyl estradiol | ||
| 20 | 3.45 | 3.38 |
| 25 | 0.47 | 0.46 |
| 30 | 8.39 | 8.31 |
| Drospirenone, μg ethinyl estradiol | ||
| 20 | 7.46 | 8.45 |
| 30 | 20.81 | 21.02 |
| Levonorgestrel, μg ethinyl estradiol | ||
| 20 | 5.19 | 5.14 |
| 30 | 3.75 | 3.72 |
| Triphasic | 2.35 | 2.11 |
| Norethindrone, μg ethinyl estradiol | ||
| 35 | 10.53 | 10.28 |
| Norethindrone acetate, μg ethinyl estradiol | ||
| 20 | 4.60 | 4.48 |
| 30 | 2.74 | 2.66 |
| 35 | 1.51 | 1.55 |
| Norgestimate, ethinyl-estradiol μg | ||
| 25 | 5.78 | 5.68 |
| 35 | 18.31 | 18.21 |
| Norgestrel, μg ethinyl estradiol | ||
| 30 | 4.66 | 4.55 |
↵* Defined as a claim for polycystic ovary syndrome (International Classification of Disease, 9th Revision [Clinical Modification (ICD-9-CM)] 256.4).
↵† Initiated combined oral contraceptive therapy after the polycystic ovary syndrome claim.
↵‡ Evidence of combined oral contraceptive use during the 365-day period before the polycystic ovary syndrome claim.